Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 850 citations

Medicine, Oncology, Pharmacology +17

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 474 citations · Full text

Pharmacy, Immunology, Oncology +17

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander Starodub, Allyson J. Ocean, Manish A. Shah et al. · Clinical Cancer Research · 2015 · 344 citations · Full text

Medicine, Oncology, Pharmacology +17

Upregulation of Trop-2 quantitatively stimulates human cancer growth

Marco Trerotola, Pamela Cantanelli, Emanuela Guerra et al. · Oncogene · 2012 · 324 citations

Medicine, Cancer Biology, Oncology +12